Crown Bioscience announced the appointment of Laurie Heilmann as Chief Business Officer. Since 2014, Heilmann has served as Crown Bioscience’s Sr. Vice President; Global Strategy, Business Development, Marketing.
“Laurie is the ideal leader for our strategic commercial operations, possessing a diverse therapeutic background and over three decades of experience aligning sales and marketing with R&D to steer company strategy,” said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. “As Sr. Vice President; Global Strategy, Business Development, Marketing, Laurie led Crown Bioscience through three years of sustained, exponential growth and guided expansion of our innovative scientific technology platform. I am excited to continue working closely with Laurie to provide our clients with the insight and understanding they need to advance their preclinical research projects.”
Heilmann is an active member of numerous industry organizations, and holds a bachelor’s degree in science and business administration. She possesses a therapeutic and life science technology background which includes cardiovascular, oncology, immunology and metabolic disease and over three decades of global experience aligning sales and marketing with R&D to steer company strategy. As Chief Business Officer, Heilmann will be responsible for world-wide sales, strategy and marketing at Crown Bioscience.
“I am honored to be assuming the role of Chief Business Officer at Crown Bioscience,” said Heilmann. “I look forward to continuing to work with Dr. Wery and our talented, dedicated team of scientists, business development and marketing professionals building our translational technology platform to help our clients address global health challenges.”